FDA clears Eko's digital stethoscope AI for spotting cases of afib, heart murmur

Duo and app on a smartphone
The atrial fibrillation and heart murmur offerings represent the first in the company’s plans to provide a full suite of automated cardiac screening tools. (Eko)

Digital stethoscope company Eko has received FDA clearance for its artificial intelligence-powered algorithms to help detect heart conditions such as murmurs and atrial fibrillation during a routine physical.

“Our vision since day one has been to build seamless technology that helps providers more accurately detect heart disease, the leading killer in the world, by putting the ears of a cardiologist in any clinician’s stethoscope,” Eko co-founder and CEO Connor Landgraf said in a statement.

The afib and heart murmur offerings represent the first in the company’s plans to provide a full suite of automated cardiac screening tools. Last month, Eko received a breakthrough designation from the FDA for an electrocardiogram-based algorithm for spotting low ejection fraction as a sign of heart failure.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

RELATED: Eko bags $20M to expand digital stethoscope, grow footprint

According to Eko, its AI algorithm can detect afib arrythmias with 99% sensitivity and 97% specificity using its Duo stethoscope. First cleared in June 2017, the device captures heart sounds alongside a one-lead ECG during a standard doctor’s office exam. It’s also able to uncover difficult-to-hear murmurs with a sensitivity and specificity of 87%, which can be a sign of a faulty heart valve.

RELATED: Eko AI study demonstrates accurate digital diagnoses of pediatric heart murmurs without a specialist

These asymptomatic conditions often go unseen during an annual physical, the company said. The algorithm also measures heart rate and QRS duration, and can identify cases of tachycardia and bradycardia.

The latest clearance covers the AI’s use in adults and in conjunction with a physician’s diagnosis.

Suggested Articles

The VC shop raised the money across two funds that will deploy cash to help biotechs get started and grow into more established players.

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.